Total Payments
$186,004
2024 Payments
$15,844
Companies
6
Transactions
99
Payment Breakdown by Category
Consulting$78,128 (42.0%)
Travel$62,685 (33.7%)
Other$36,204 (19.5%)
Research$6,609 (3.6%)
Food & Beverage$2,377 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $78,128 | 34 | 42.0% |
| Travel and Lodging | $62,685 | 28 | 33.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $28,858 | 8 | 15.5% |
| Honoraria | $7,346 | 1 | 3.9% |
| Unspecified | $6,609 | 1 | 3.6% |
| Food and Beverage | $2,377 | 27 | 1.3% |
Payments by Type
General
$179,395
98 transactions
Research
$6,609
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Chiesi USA, Inc. | $73,629 | 20 | $0 (2024) |
| GENZYME CORPORATION | $56,995 | 57 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $26,093 | 5 | $0 (2020) |
| Amicus Therapeutics, Inc. | $20,985 | 12 | $0 (2021) |
| IDORSIA PHARMACEUTICALS US INC | $5,287 | 3 | $0 (2024) |
| Actelion Clinical Research, Inc. | $3,015 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $15,844 | 6 | Chiesi USA, Inc. ($13,807) |
| 2023 | $17,371 | 7 | Chiesi USA, Inc. ($14,121) |
| 2022 | $18,311 | 3 | Chiesi USA, Inc. ($18,311) |
| 2021 | $13,831 | 5 | Chiesi USA, Inc. ($10,081) |
| 2020 | $42,793 | 10 | SANOFI-AVENTIS U.S. LLC ($26,093) |
| 2019 | $18,473 | 11 | Amicus Therapeutics, Inc. ($11,235) |
| 2018 | $10,307 | 18 | GENZYME CORPORATION ($10,307) |
| 2017 | $49,075 | 39 | GENZYME CORPORATION ($46,060) |
All Payment Transactions
99 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/02/2024 | Chiesi USA, Inc. | ELFABRIO (Drug) | Travel and Lodging | Cash or cash equivalent | $13,350.00 | General |
| Category: ERT FOR FABRY DISEASE | ||||||
| 10/02/2024 | Chiesi USA, Inc. | ELFABRIO (Drug) | Consulting Fee | Cash or cash equivalent | $222.00 | General |
| Category: ERT FOR FABRY DISEASE | ||||||
| 10/02/2024 | Chiesi USA, Inc. | ELFABRIO (Drug) | Food and Beverage | Cash or cash equivalent | $140.36 | General |
| Category: ERT FOR FABRY DISEASE | ||||||
| 06/04/2024 | IDORSIA PHARMACEUTICALS US INC | Lucerastat | Food and Beverage | In-kind items and services | $87.03 | General |
| 02/06/2024 | Chiesi USA, Inc. | ELFABRIO (Drug) | Food and Beverage | Cash or cash equivalent | $94.72 | General |
| Category: ERT FOR FABRY DISEASE | ||||||
| 01/15/2024 | IDORSIA PHARMACEUTICALS US INC | Lucerastat | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| 09/14/2023 | Chiesi USA, Inc. | ELFABRIO (Drug) | Travel and Lodging | Cash or cash equivalent | $11,236.27 | General |
| Category: ERT FOR FABRY DISEASE | ||||||
| 09/14/2023 | Chiesi USA, Inc. | ELFABRIO (Drug) | Consulting Fee | Cash or cash equivalent | $808.70 | General |
| Category: ERT FOR FABRY DISEASE | ||||||
| 06/05/2023 | IDORSIA PHARMACEUTICALS US INC | LUCERASTAT | Consulting Fee | Cash or cash equivalent | $3,250.00 | General |
| 04/06/2023 | Chiesi USA, Inc. | ELFABRIO (Drug) | Travel and Lodging | Cash or cash equivalent | $1,236.57 | General |
| Category: ERT FOR FABRY DISEASE | ||||||
| 04/06/2023 | Chiesi USA, Inc. | ELFABRIO (Drug) | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| Category: ERT FOR FABRY DISEASE | ||||||
| 02/24/2023 | Chiesi USA, Inc. | ELFABRIO (Drug) | Food and Beverage | Cash or cash equivalent | $33.76 | General |
| Category: ERT FOR FABRY DISEASE | ||||||
| 01/29/2023 | Chiesi USA, Inc. | FERRIPROX (Drug) | Travel and Lodging | Cash or cash equivalent | $455.67 | General |
| Category: TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | ||||||
| 09/29/2022 | Chiesi USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $8,140.00 | General |
| 07/12/2022 | Chiesi USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,825.00 | General |
| 02/25/2022 | Chiesi USA, Inc. | — | Honoraria | Cash or cash equivalent | $7,346.00 | General |
| 12/22/2021 | Amicus Therapeutics, Inc. | GALAFOLD (Drug) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: FABRY DISEASE | ||||||
| 11/04/2021 | Chiesi USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,955.79 | General |
| 05/13/2021 | Chiesi USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 02/25/2021 | Amicus Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 02/12/2021 | Chiesi USA, Inc. | FERRIPROX (Drug) | Consulting Fee | Cash or cash equivalent | $3,625.00 | General |
| Category: HEMATOLOGY, DISEASE | ||||||
| 12/10/2020 | Amicus Therapeutics, Inc. | GALAFOLD (Drug) | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| Category: Fabry Disease | ||||||
| 12/10/2020 | Amicus Therapeutics, Inc. | GALAFOLD (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Fabry Disease | ||||||
| 10/08/2020 | CHIESI USA, INC. | — | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| 07/09/2020 | CHIESI USA, INC. | — | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NONE | Chiesi USA, Inc. | $6,609 | 1 |
About Dr. David Warnock, MD
Dr. David Warnock, MD is a Nephrology healthcare provider based in Birmingham, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1902816929.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Warnock, MD has received a total of $186,004 in payments from pharmaceutical and medical device companies, with $15,844 received in 2024. These payments were reported across 99 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($78,128).
Ad
Practice Information
- Specialty Nephrology
- Location Birmingham, AL
- Active Since 08/09/2006
- Last Updated 07/13/2011
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1902816929
Products in Payments
- FABRAZYME (Drug) $40,209
- ELFABRIO (Drug) $27,472
- FABRAZYME (Biological) $26,093
- GALAFOLD (Drug) $17,985
- NO PRODUCT DISCUSSED (Drug) $11,136
- DISEASE STATE (Drug) $5,649
- FERRIPROX (Drug) $4,081
- LUCERASTAT $3,250
- Lucerastat $2,037
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Birmingham
Eric Wallace
Nephrology — Payments: $137,132
Nephrology $137,132
Dana Rizk
Nephrology — Payments: $124,680
Nephrology $124,680
Michal Mrug
Nephrology — Payments: $92,833
Nephrology $92,833
Ashita Tolwani
Nephrology — Payments: $67,643
Nephrology $67,643
Timmy Lee
Nephrology — Payments: $38,311
Nephrology $38,311
Vineeta Kumar
Nephrology — Payments: $34,582
Nephrology $34,582